NSPR Stock Overview
A medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
InspireMD, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.64 |
| 52 Week High | US$3.42 |
| 52 Week Low | US$1.81 |
| Beta | 0.93 |
| 11 Month Change | 6.02% |
| 3 Month Change | -7.37% |
| 1 Year Change | 10.46% |
| 33 Year Change | -28.46% |
| 5 Year Change | -82.25% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Here's Why We're Not Too Worried About InspireMD's (NASDAQ:NSPR) Cash Burn Situation
Jan 11
We Think InspireMD (NASDAQ:NSPR) Needs To Drive Business Growth Carefully
Jan 27We're Keeping An Eye On InspireMD's (NASDAQ:NSPR) Cash Burn Rate
Oct 05InspireMD: Revolutionizing The Field Of Vascular Stenting
Sep 20Trade Alert: Gary Roubin At InspireMD, Inc. (NYSEMKT:NSPR), Has Just Spent US$150k Buying 52% More Shares
Feb 11Shareholder Returns
| NSPR | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 5.2% | -0.4% | -1.0% |
| 1Y | 10.5% | 20.3% | 30.3% |
Return vs Industry: NSPR underperformed the US Medical Equipment industry which returned 20.9% over the past year.
Return vs Market: NSPR underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| NSPR volatility | |
|---|---|
| NSPR Average Weekly Movement | 5.9% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NSPR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NSPR's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 80 | Marvin Slosman | www.inspiremd.com |
InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions.
InspireMD, Inc. Fundamentals Summary
| NSPR fundamental statistics | |
|---|---|
| Market cap | US$67.04m |
| Earnings (TTM) | -US$28.24m |
| Revenue (TTM) | US$6.82m |
10.1x
P/S Ratio-2.4x
P/E RatioIs NSPR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NSPR income statement (TTM) | |
|---|---|
| Revenue | US$6.82m |
| Cost of Revenue | US$5.28m |
| Gross Profit | US$1.54m |
| Other Expenses | US$29.78m |
| Earnings | -US$28.24m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.08 |
| Gross Margin | 22.61% |
| Net Profit Margin | -413.96% |
| Debt/Equity Ratio | 0% |
How did NSPR perform over the long term?
See historical performance and comparison